Intermittent Fasting and CLL/SLL

Plain-language summary

This study examines the effects of intermittent fasting in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It enrolled patients aged 85 and under with a diagnosis of CLL or SLL who had not received lymphoma therapy in the past 3 months. The study was conducted in Phase 1 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 1

Status

Completed

Sponsor

Eleah Stringer

Intervention

Intermittent fast

Start date

2/3/2021

Estimated completion

12/31/2022

Countries

Canada

Related genes

Locations

• Victoria, Canada

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Diagnosis of CLL or SLL
* Age \</=85
* Lymphocytes \>/=40 and \<150
* Hemoglobin \>/=100g/L
* Platelet \>100 x 10\*9/L
* BMI of \>/= 20kg/m2
* Eastern Cooperative Oncology Group (ECOG) Performance Status \</=2
* Not on anti-lymphoma therapy within the past 3 months
* Not receiving anti-lymphoma therapy and not expected to require initiation of anti-lymphoma therapy within the next 3 months

Exclusion Criteria:

* Patient unable to give consent
* Patient on medications required to be taken with food during the fasting window
* Pregnancy
* Diabetes mellitus
* BMI drop to \</= 18.5kg/m2 at any time during study